The first participants have been selected to join the aiForward program. Their projects explore the usage and advantages of deep learning AI in cancer research. Learn more about the participants and their research projects below.

Reidunn Edelmann, PhD

Dr. Edelmann is a postdoctoral researcher in Arne Östman’s laboratory at the Centre for Cancer Biomarkers, University of Bergen, Norway.

Her project aims to develop a method for tumor vessel annotation which identifies marker-defined subsets of vessels that are expected to display different functional properties. Manual annotation is time-consuming and possibly error-prone. “Our AI-based approach takes tumor vessel annotation to a new level, with the promise of a more comprehensive characterization of different vessel phenotypes. This could possibly lead to discovery of biologically meaningful and well-performing vessel-related biomarkers,” states Dr. Edelmann.

Liesbeth Hondelink, MSc student

Ms. Hondelink is an MSc student from Dr. Danielle Cohens’ laboratory, Leiden University Medical Center, the Netherlands. She applied to the aiForward program to develop an algorithm for the scoring of a diagnostic marker molecule in tumor cells. According to Ms. Hondelink, the accuracy of tumor cell scoring is currently affected by inter- and intra-observer variability.

“We have already seen great and promising advances in AI-based sample image analysis,” says Ms. Hondelink. “In order to more adequately identify the patients that could benefit from immunotherapy, a more precise scoring method is essential.”

Interested in joining aiForward? Applications for the program are accepted on a continuous basis.

Apply now

aiForward is created by Aiforia, the developer of the state-of-the-art Aiforia platform and Aiforia® Create tool. Aiforia is a University of Helsinki spin-off founded in 2013.